Subscribe

Stratec SE (SBS.DE)

EUR18.20 +0.20 (+1.11%)
DE XETRA Healthcare Medical - Diagnostics & Research
Address Gewerbestrasse 37 75217
Birkenfeld, DE
CEO Marcus Wolfinger
Website stratec.com
IPO 2000-06-16
ISIN DE000STRA555

Explore sections of this company profile

Also trades on Deutsche Börse · SBS.DE (EUR) London Stock Exchange · 0RAR.L (EUR) Other OTC · STSEY (USD)
Description

Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumentation systems. The company caters to the in-vitro diagnostics and life sciences sectors, operating across Germany, the European Union, and globally. Its business is divided into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on designing and fabricating automated analytical systems, along with necessary spare parts and supplies, for customers in clinical diagnostics and biotechnology. The Diatron segment provides a suite of systems, components, disposables, and assays for lower-volume hematology and clinical chemistry applications. Finally, the Smart Consumables segment is dedicated to engineering and producing intelligent consumables for the diagnostics, life sciences, and medical technology industries.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR18.20 +0.20 (+1.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
14.3K
Beta
0.80
Float Shares
7.58M
Free Float %
62.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.05% -2.58% -1.14% -12.85% -18.31% -21.45% -30.42% -72.49% -84.13% -65.87% -16.86%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
18.20
DCF (Unlevered) 46.28 +154.3%
DCF (Levered) 20.74 +14.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 67% Bullish
Rating 2026-05 Change
Strong Buy 0 -1
Buy 4 0
Hold 2 0
Sell 0 0
Strong Sell 0 0
Quality scores
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Diagnostics & Research: +7.9%
    -2.6% Q1'26: -9.9% (vs Q1'25)
  • ✗
    EPS growth Medical - Diagnostics & Research: +30.8%
    -101.5% Q1'26: +27.3% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    -6.4% Q1'26: -2.2% (vs Q1'25)
  • ✗
    EBIT margin Medical - Diagnostics & Research: +9.6%
    +3.4% Q1'26: -0.8% (vs Q1'25)
  • ✗
    ROIC Medical - Diagnostics & Research: +5.2%
    +1.5% Q1'26: -0.8% (vs Q1'25)
  • ✓
    Share dilution Medical - Diagnostics & Research: 0.0%
    +0.0% ★ Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    4.86× Q1'26: -8.41× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.80) × ERP
WACC = 62% × Ke + 38% × Kd (4.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 46.28 Current price: 18.20
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
5 Rev. Ana.
2 EPS Ana. 		Dec 2027
6 Rev. Ana.
4 EPS Ana. 		Dec 2028
4 Rev. Ana.
3 EPS Ana. 		Dec 2029
3 Rev. Ana.
1 EPS Ana. 		Dec 2030
3 Rev. Ana.
1 EPS Ana.
Revenue
122.20M
est: 119.85M (+2.0%)
122.42M
est: 124.61M (-1.8%)
127.95M
est: 130.99M (-2.3%)
144.86M
est: 147.84M (-2.0%)
146.89M
est: 147.11M (-0.2%)
184.91M
est: 184.17M (+0.4%)
209.76M
est: 213.98M (-2.0%)
187.82M
est: 198.60M (-5.4%)
221.64M
est: 220.62M (+0.5%)
250.10M
est: 251.60M (-0.6%)
287.34M
est: 287.91M (-0.2%)
274.63M
est: 274.69M (0.0%)
270.41M
est: 255.98M (+5.6%)
257.62M
est: 261.08M (-1.3%)
250.86M
est: 251.73M (-0.3%)
264.19M
255.93M – 283.10M
+5.0% YoY
281.66M
264.93M – 298.05M
+6.6% YoY
299.54M
298.54M – 300.54M
+6.3% YoY
326.71M
311.75M – 347.83M
+9.1% YoY
351.17M
335.08M – 373.87M
+7.5% YoY
EBITDA
25.57M
est: 24.00M (+6.5%)
21.55M
est: 25.54M (-15.6%)
26.12M
est: 22.14M (+18.0%)
32.47M
est: 29.10M (+11.6%)
33.59M
est: 33.67M (-0.2%)
35.06M
est: 40.76M (-14.0%)
48.30M
est: 39.30M (+22.9%)
36.40M
est: 42.39M (-14.1%)
36.09M
est: 35.51M (+1.6%)
56.72M
est: 40.13M (+41.4%)
66.52M
est: 44.10M (+50.8%)
57.53M
est: 47.92M (+20.0%)
43.16M
est: 45.71M (-5.6%)
47.34M
est: 46.27M (+2.3%)
27.19M
est: 44.95M (-39.5%)
47.17M
45.70M – 50.55M
+5.0% YoY
50.29M
47.30M – 53.22M
+6.6% YoY
53.48M
53.30M – 53.66M
+6.3% YoY
58.33M
55.66M – 62.11M
+9.1% YoY
62.70M
59.83M – 66.75M
+7.5% YoY
EBIT
21.71M
est: 20.44M (+6.2%)
15.64M
est: 22.67M (-31.0%)
19.57M
est: 18.50M (+5.8%)
24.27M
est: 21.93M (+10.7%)
27.35M
est: 25.08M (+9.1%)
23.85M
est: 32.48M (-26.6%)
29.73M
est: 28.87M (+3.0%)
14.68M
est: 27.59M (-46.8%)
17.39M
est: 16.61M (+4.7%)
34.13M
est: 22.05M (+54.8%)
48.26M
est: 24.23M (+99.2%)
40.60M
est: 26.33M (+54.2%)
25.54M
est: 28.29M (-9.7%)
27.91M
est: 28.64M (-2.6%)
8.59M
est: 27.82M (-69.1%)
29.20M
28.29M – 31.29M
+5.0% YoY
31.13M
29.28M – 32.94M
+6.6% YoY
33.10M
32.99M – 33.21M
+6.3% YoY
36.11M
34.45M – 38.44M
+9.1% YoY
38.81M
37.03M – 41.32M
+7.5% YoY
Net Income
15.28M
est: 15.10M (+1.2%)
13.97M
est: 15.91M (-12.2%)
15.48M
est: 14.72M (+5.2%)
19.77M
est: 17.43M (+13.4%)
22.08M
est: 20.61M (+7.1%)
19.57M
est: 26.69M (-26.7%)
25.64M
est: 23.33M (+9.9%)
8.97M
est: 23.73M (-62.2%)
14.44M
est: 9.93M (+45.5%)
25.18M
est: 16.69M (+50.8%)
39.96M
est: 18.34M (+117.9%)
29.22M
est: 19.93M (+46.6%)
15.37M
est: 14.58M (+5.5%)
16.02M
est: 20.72M (-22.7%)
-242.0K
est: 15.89M (-101.5%)
17.08M
16.76M – 17.41M
+7.5% YoY
21.68M
17.43M – 25.94M
+26.9% YoY
17.95M
17.53M – 30.94M
-17.2% YoY
27.53M
25.89M – 29.84M
+53.4% YoY
31.49M
29.62M – 34.14M
+14.4% YoY
SGA
15.72M
est: 36.58M (-57.0%)
18.00M
est: 37.33M (-51.8%)
15.96M
est: 19.45M (-17.9%)
17.11M
est: 18.00M (-4.9%)
18.40M
est: 17.84M (+3.1%)
28.77M
est: 22.23M (+29.4%)
30.56M
est: 34.43M (-11.2%)
23.85M
est: 28.29M (-15.7%)
26.14M
est: 26.40M (-1.0%)
27.68M
est: 31.67M (-12.6%)
28.26M
est: 34.81M (-18.8%)
30.25M
est: 37.82M (-20.0%)
31.21M
est: 31.84M (-2.0%)
36.90M
est: 32.23M (+14.5%)
38.80M
est: 31.31M (+23.9%)
32.86M
31.83M – 35.21M
+5.0% YoY
35.03M
32.95M – 37.07M
+6.6% YoY
37.25M
37.13M – 37.38M
+6.3% YoY
40.63M
38.77M – 43.26M
+9.1% YoY
43.67M
41.67M – 46.50M
+7.5% YoY
EPS
1.32
est: 1.38 (-4.6%)
1.06
est: 1.27 (-16.6%)
1.32
est: 1.34 (-1.5%)
1.68
est: 1.69 (-0.6%)
1.87
est: 1.90 (-1.5%)
1.65
est: 1.92 (-14.0%)
2.16
est: 2.25 (-4.0%)
0.75
est: 1.58 (-52.5%)
1.20
est: 2.11 (-43.1%)
2.42
est: 2.82 (-14.2%)
3.30
est: 3.69 (-10.5%)
2.41
est: 2.84 (-15.0%)
1.26
est: 1.20 (+5.1%)
1.32
est: 1.68 (-21.6%)
-0.02
est: 1.29 (-101.5%)
1.41
1.38 – 1.43
+8.8% YoY
1.70
1.43 – 2.13
+21.2% YoY
2.00
1.44 – 2.55
+17.3% YoY
2.26
2.13 – 2.45
+13.3% YoY
2.59
2.44 – 2.81
+14.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-08 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-07 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-06 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-05 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-04 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-29 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-28 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-27 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-24 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-23 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-22 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-21 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-20 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-17 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-16 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-13.38M
OE per share TTM
-1.10
Owner's Yield
-6.22%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
27.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 6 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Dimensional - International Small Cap ETF DFIS 0.01% 413.8K 0.39%
2 Avantis International Small Cap Equity ETF AVDS 0.01% 16.8K 0.30%
3 Dimensional - International Small Cap Value ETF DISV 0.00% 212.9K 0.42%
4 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 77.5K 0.28%
5 Avantis International Equity ETF AVDE 0.00% 112.7K 0.23%
6 Dimensional - International Core Equity 2 ETF DFIC 0.00% 45.3K 0.22%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
5.9K
Shares Outstanding
12.16M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Marcus Wolfinger Chairman of Board of Management & Chief Executive Officer 764.0K male
Claus Vielsack Director of Product Development & Member of Board of Management 567.0K —
Georg Bauer Director for Sales & Member of Management Board 451.0K —
Hermann Leistner Founder & Advisor — male
Jan Keppeler Head of Investor Relations, Sustainability & Corporate Communications — male
Tanja Bucherl Chief Financial Officer & Member of Management Board — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research